Clinical Trial Update: A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating elacestrant versus standard endocrine therapy in ER+, HER2-, early breast cancer at high risk of recurrence; recruitment is on…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Elacestrant (elacestrant)

Snippet

Sponsor: Stemline Therapeutics, Inc. | Conditions: Breast Cancer | Phase 3 | Status: RECRUITING